Clinical Trial Update: A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) [Phase 2]

View source ↗

Summary

Phase 2 study of the IDd regimen (ixazomib, daratumumab, dexamethasone) in relapsed/refractory multiple myeloma has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Darzalex (daratumumab) (daratumumab)
• Decadron (dexamethasone) (dexamethasone)
• Ninlaro (ixazomib) (ixazomib)

Snippet

Sponsor: Takeda | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2023-02-08